Biosearch Wins Phase II SBIR from DoD to Develop RT-qPCR Tests for Exotic Pathogens | GenomeWeb

Biosearch Technologies said yesterday that it has been awarded an $800,000 Small Business Innovation Research grant from the US Department of Defense to design and develop reverse transcriptase quantitative PCR assays to test for pathogens of military importance.

Under the Phase II SBIR grant, Novato, Calif.-based Biosearch will modify the assays for field deployment in overseas military operations, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.